Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Jul;65(7):2803–2811. doi: 10.1128/iai.65.7.2803-2811.1997

A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats.

D J Brackett 1, M R Lerner 1, M A Lacquement 1, R He 1, H A Pereira 1
PMCID: PMC175395  PMID: 9199453

Abstract

The lipid A component of lipopolysaccharide (LPS) derived from Escherichia coli has been implicated as a significant mediator in the development of circulatory and metabolic dysfunction and lethality associated with sepsis. A synthetic peptide corresponding to amino acid residues 20 through 44 of the neutrophil-derived 37-kDa cationic antimicrobial protein (CAP37 P(20-44)) possesses lipid A binding characteristics which may be useful in attenuating in vivo responses induced during circumstances of endotoxemia, including sepsis. The E. coli LPS to be used in the in vivo study was shown to be attenuated by CAP37 P(20-44) in a dose-dependent manner in the in vitro reaction with Limulus amoebocyte lysate. Intravenous infusion of CAP37 P(20-44) (1.5 or 3.0 mg/kg of body weight) with E. coli LPS (250 microg/kg over 30 min) into conscious, unrestrained rats prevented LPS-induced hyperdynamic and hypodynamic circulatory shock, hyperlactacidemia, and leukopenia in a dose-related fashion. CAP37 P(20-44) (0.2, 1.0, and 5.0 mg/kg) administered intravenously to conscious, actinomycin D-sensitized rats following a lethal dose of LPS neutralized LPS toxicity, resulting in dose-dependent 7-day survival rates of 30, 50, and 80%, respectively. CAP37 P(20-44) (5.0 mg/kg) significantly inhibited the endotoxin-induced increase in circulating tumor necrosis factor alpha in sensitized rats. These data demonstrate that CAP37 P(20-44) has the capacity to abolish in vivo biological responses to LPS that are relevant to human sepsis and to significantly neutralize the toxicity of circulating E. coli LPS.

Full Text

The Full Text of this article is available as a PDF (373.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammons W. S., Kung A. H. Recombinant amino terminal fragment of bactericidal/permeability-increasing protein prevents hemodynamic responses to endotoxin. Circ Shock. 1993 Nov;41(3):176–184. [PubMed] [Google Scholar]
  2. Bauss F., Dröge W., Männel D. N. Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun. 1987 Jul;55(7):1622–1625. doi: 10.1128/iai.55.7.1622-1625.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bengtson A., Hansson G. K., Heideman M. In vivo determination of modulated migration of radiolabeled leukocytes. Arch Surg. 1987 Aug;122(8):909–912. doi: 10.1001/archsurg.1987.01400200059010. [DOI] [PubMed] [Google Scholar]
  4. Beutler B., Cerami A. Cachectin/tumor necrosis factor: an endogenous mediator of shock and inflammation. Immunol Res. 1986;5(4):281–293. doi: 10.1007/BF02935501. [DOI] [PubMed] [Google Scholar]
  5. Biber B., Schaefer C. F., Smolik M. J., Lawrence M. C., Lerner M. R., Brackett D. J., Wilson M. F., Fagraeus L. Dose-related effects of isoflurane on superior mesenteric vasoconstriction induced by endotoxemia in the rat. Acta Anaesthesiol Scand. 1987 Jul;31(5):430–437. doi: 10.1111/j.1399-6576.1987.tb02597.x. [DOI] [PubMed] [Google Scholar]
  6. Brackett D. J., Gauvin D. V., Lerner M. R., Holloway F. A., Wilson M. F. Dose- and time-dependent cardiovascular responses induced by ethanol. J Pharmacol Exp Ther. 1994 Jan;268(1):78–84. [PubMed] [Google Scholar]
  7. Brackett D. J., Schaefer C. F., Tompkins P., Fagraeus L., Peters L. J., Wilson M. F. Evaluation of cardiac output, total peripheral vascular resistance, and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ Shock. 1985;17(4):273–284. [PubMed] [Google Scholar]
  8. Brogden K. A., Phillips M. The ultrastructural morphology of endotoxins and lipopolysaccharides. Electron Microsc Rev. 1988;1(2):261–278. doi: 10.1016/0892-0354(88)90004-4. [DOI] [PubMed] [Google Scholar]
  9. Cannon J. G., Tompkins R. G., Gelfand J. A., Michie H. R., Stanford G. G., van der Meer J. W., Endres S., Lonnemann G., Corsetti J., Chernow B. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990 Jan;161(1):79–84. doi: 10.1093/infdis/161.1.79. [DOI] [PubMed] [Google Scholar]
  10. Cody C. S., Burd R. S., Mayoral J. L., Dunn D. L. Protective anti-lipopolysaccharide monoclonal antibodies inhibit tumor necrosis factor production. J Surg Res. 1992 Apr;52(4):314–319. doi: 10.1016/0022-4804(92)90109-d. [DOI] [PubMed] [Google Scholar]
  11. Coran A. G., Drongowski R. A., Paik J. J., Remick D. G. Ibuprofen intervention in canine septic shock: reduction of pathophysiology without decreased cytokines. J Surg Res. 1992 Sep;53(3):272–279. doi: 10.1016/0022-4804(92)90047-4. [DOI] [PubMed] [Google Scholar]
  12. Danner R. L., Elin R. J., Hosseini J. M., Wesley R. A., Reilly J. M., Parillo J. E. Endotoxemia in human septic shock. Chest. 1991 Jan;99(1):169–175. doi: 10.1378/chest.99.1.169. [DOI] [PubMed] [Google Scholar]
  13. Flynn P. M., Shenep J. L., Gigliotti F., Davis D. S., Hildner W. K. Immunolabeling of lipopolysaccharide liberated from antibiotic-treated Escherichia coli. Infect Immun. 1988 Oct;56(10):2760–2762. doi: 10.1128/iai.56.10.2760-2762.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fujihara Y., Bogard W. C., Lei M. G., Daddona P. E., Morrison D. C. Monoclonal anti-lipid A IgM antibodies HA-1A and E-5 recognize distinct epitopes on lipopolysaccharide and lipid A. J Infect Dis. 1993 Dec;168(6):1429–1435. doi: 10.1093/infdis/168.6.1429. [DOI] [PubMed] [Google Scholar]
  15. Galanos C., Freudenberg M. A. Mechanisms of endotoxin shock and endotoxin hypersensitivity. Immunobiology. 1993 Apr;187(3-5):346–356. doi: 10.1016/S0171-2985(11)80349-9. [DOI] [PubMed] [Google Scholar]
  16. Galanos C., Lüderitz O., Rietschel E. T., Westphal O., Brade H., Brade L., Freudenberg M., Schade U., Imoto M., Yoshimura H. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem. 1985 Apr 1;148(1):1–5. doi: 10.1111/j.1432-1033.1985.tb08798.x. [DOI] [PubMed] [Google Scholar]
  17. Issekutz A. C., Bhimji S. Role for endotoxin in the leukocyte infiltration accompanying Escherichia coli inflammation. Infect Immun. 1982 May;36(2):558–566. doi: 10.1128/iai.36.2.558-566.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jin H., Yang R., Marsters S., Ashkenazi A., Bunting S., Marra M. N., Scott R. W., Baker J. B. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest. 1995 Apr;95(4):1947–1952. doi: 10.1172/JCI117877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Johnston T. D., Hampton W. W., Fry D. E. Septic hemodynamics produced by infusion of endotoxin. Curr Surg. 1989 Mar-Apr;46(2):101–103. [PubMed] [Google Scholar]
  20. Kohn F. R., Ammons W. S., Horwitz A., Grinna L., Theofan G., Weickmann J., Kung A. H. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. J Infect Dis. 1993 Nov;168(5):1307–1310. doi: 10.1093/infdis/168.5.1307. [DOI] [PubMed] [Google Scholar]
  21. Kubo K., Kobayashi T., Hayano T., Koizumi T., Honda T., Sekiguchi M., Sakai A. Effects of ONO-5046, a specific neutrophil elastase inhibitor, on endotoxin-induced lung injury in sheep. J Appl Physiol (1985) 1994 Sep;77(3):1333–1340. doi: 10.1152/jappl.1994.77.3.1333. [DOI] [PubMed] [Google Scholar]
  22. Kurose I., Suematsu M., Miura S., Fukumura D., Sekizuka E., Nagata H., Oshio C., Tsuchiya M. Oxyradical generation from leukocytes during endotoxin-induced microcirculatory disturbance in rat mesentery--attenuating effect of cetraxate. Toxicol Appl Pharmacol. 1993 May;120(1):37–44. doi: 10.1006/taap.1993.1084. [DOI] [PubMed] [Google Scholar]
  23. Lasfargues A., Tahri-Jouti M. A., Pedron T., Girard R., Chaby R. Effects of lipopolysaccharide on macrophages analyzed with anti-lipid A monoclonal antibodies and polymyxin B. Eur J Immunol. 1989 Dec;19(12):2219–2225. doi: 10.1002/eji.1830191207. [DOI] [PubMed] [Google Scholar]
  24. Lin R. Y., Astiz M. E., Saxon J. C., Saha D. C., Rackow E. C. Relationships between plasma cytokine concentrations and leukocyte functional antigen expression in patients with sepsis. Crit Care Med. 1994 Oct;22(10):1595–1602. [PubMed] [Google Scholar]
  25. Martich G. D., Danner R. L., Ceska M., Suffredini A. F. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med. 1991 Apr 1;173(4):1021–1024. doi: 10.1084/jem.173.4.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Martich G. D., Parker M. M., Cunnion R. E., Suffredini A. F. Effects of ibuprofen and pentoxifylline on the cardiovascular response of normal humans to endotoxin. J Appl Physiol (1985) 1992 Sep;73(3):925–931. doi: 10.1152/jappl.1992.73.3.925. [DOI] [PubMed] [Google Scholar]
  27. Merrifield B. Solid phase synthesis. Science. 1986 Apr 18;232(4748):341–347. doi: 10.1126/science.3961484. [DOI] [PubMed] [Google Scholar]
  28. Michie H. R., Manogue K. R., Spriggs D. R., Revhaug A., O'Dwyer S., Dinarello C. A., Cerami A., Wolff S. M., Wilmore D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988 Jun 9;318(23):1481–1486. doi: 10.1056/NEJM198806093182301. [DOI] [PubMed] [Google Scholar]
  29. Michie H. R., Spriggs D. R., Manogue K. R., Sherman M. L., Revhaug A., O'Dwyer S. T., Arthur K., Dinarello C. A., Cerami A., Wolff S. M. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 1988 Aug;104(2):280–286. [PubMed] [Google Scholar]
  30. Moore F. D., Jr, Socher S. H., Davis C. Tumor necrosis factor and endotoxin can cause neutrophil activation through separate pathways. Arch Surg. 1991 Jan;126(1):70–73. doi: 10.1001/archsurg.1991.01410250076012. [DOI] [PubMed] [Google Scholar]
  31. Morgan J. G., Sukiennicki T., Pereira H. A., Spitznagel J. K., Guerra M. E., Larrick J. W. Cloning of the cDNA for the serine protease homolog CAP37/azurocidin, a microbicidal and chemotactic protein from human granulocytes. J Immunol. 1991 Nov 1;147(9):3210–3214. [PubMed] [Google Scholar]
  32. Morrison D. C., Ulevitch R. J. The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol. 1978 Nov;93(2):526–618. [PMC free article] [PubMed] [Google Scholar]
  33. Movat H. Z. Tumor necrosis factor and interleukin-1: role in acute inflammation and microvascular injury. J Lab Clin Med. 1987 Dec;110(6):668–681. [PubMed] [Google Scholar]
  34. Mózes T., Ben-Efraim S., Tak C. J., Heiligers J. P., Saxena P. R., Bonta I. L. Serum levels of tumor necrosis factor determine the fatal or non-fatal course of endotoxic shock. Immunol Lett. 1991 Feb;27(2):157–162. doi: 10.1016/0165-2478(91)90144-y. [DOI] [PubMed] [Google Scholar]
  35. Noronha-Blob L., Lowe V. C., Weitzberg M., Burch R. M. NPC 15669 enhances survival and reverses leukopenia in endotoxin-treated mice. Eur J Pharmacol. 1991 Jul 9;199(3):387–388. doi: 10.1016/0014-2999(91)90507-m. [DOI] [PubMed] [Google Scholar]
  36. Nys M., Cloes J. M., Demonty J., Joassin L. Protective effects of polyclonal sera and of monoclonal antibodies active to Salmonella minnesota Re595 lipopolysaccharide during experimental endotoxemia. J Infect Dis. 1990 Nov;162(5):1087–1095. doi: 10.1093/infdis/162.5.1087. [DOI] [PubMed] [Google Scholar]
  37. Parent J. B., Gazzano-Santoro H., Wood D. M., Lim E., Pruyne P. T., Trown P. W., Conlon P. J. Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides. Circ Shock. 1992 Sep;38(1):63–73. [PubMed] [Google Scholar]
  38. Pedron T., Girard R., Lasfargues A., Chaby R. Differential effects of a monoclonal antibody recognizing 3-deoxy-D-manno-2-octulosonic acid on endotoxin-induced activation of pre-B cells and macrophages. Cell Immunol. 1993 Apr 15;148(1):18–31. doi: 10.1006/cimm.1993.1088. [DOI] [PubMed] [Google Scholar]
  39. Pereira H. A., Erdem I., Pohl J., Spitznagel J. K. Synthetic bactericidal peptide based on CAP37: a 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4733–4737. doi: 10.1073/pnas.90.10.4733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Pieroni R. E., Broderick E. J., Bundeally A., Levine L. A simple method for the quantitation of submicrogram amounts of bacterial endotoxin. Proc Soc Exp Biol Med. 1970 Mar;133(3):790–794. doi: 10.3181/00379727-133-34565. [DOI] [PubMed] [Google Scholar]
  41. Pohl J., Pereira H. A., Martin N. M., Spitznagel J. K. Amino acid sequence of CAP37, a human neutrophil granule-derived antibacterial and monocyte-specific chemotactic glycoprotein structurally similar to neutrophil elastase. FEBS Lett. 1990 Oct 15;272(1-2):200–204. doi: 10.1016/0014-5793(90)80484-z. [DOI] [PubMed] [Google Scholar]
  42. Raetz C. R. Biochemistry of endotoxins. Annu Rev Biochem. 1990;59:129–170. doi: 10.1146/annurev.bi.59.070190.001021. [DOI] [PubMed] [Google Scholar]
  43. Redl H., Schlag G., Bahrami S., Davies J., Jochum M., Bengtsson A. Experimental and clinical evidence of leukocyte activation in trauma and sepsis. Prog Clin Biol Res. 1994;388:221–245. [PubMed] [Google Scholar]
  44. Rietschel E. T., Brade H., Brade L., Brandenburg K., Schade U., Seydel U., Zähringer U., Galanos C., Lüderitz O., Westphal O. Lipid A, the endotoxic center of bacterial lipopolysaccharides: relation of chemical structure to biological activity. Prog Clin Biol Res. 1987;231:25–53. [PubMed] [Google Scholar]
  45. Schaefer C. F., Biber B., Brackett D. J., Schmidt C. C., Fagraeus L., Wilson M. F. Choice of anesthetic alters the circulatory shock pattern as gauged by conscious rat endotoxemia. Acta Anaesthesiol Scand. 1987 Aug;31(6):550–556. doi: 10.1111/j.1399-6576.1987.tb02619.x. [DOI] [PubMed] [Google Scholar]
  46. Schaefer C. F., Brackett D. J., Tompkins P., Wilson M. F. Anesthetic-induced changes in cardiovascular and small intestinal responses to endotoxin in the rat. Circ Shock. 1984;12(2):125–133. [PubMed] [Google Scholar]
  47. Shafer W. M., Martin L. E., Spitznagel J. K. Cationic antimicrobial proteins isolated from human neutrophil granulocytes in the presence of diisopropyl fluorophosphate. Infect Immun. 1984 Jul;45(1):29–35. doi: 10.1128/iai.45.1.29-35.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Shafer W. M., Martin L. E., Spitznagel J. K. Late intraphagosomal hydrogen ion concentration favors the in vitro antimicrobial capacity of a 37-kilodalton cationic granule protein of human neutrophil granulocytes. Infect Immun. 1986 Sep;53(3):651–655. doi: 10.1128/iai.53.3.651-655.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Shenep J. L., Flynn P. M., Barrett F. F., Stidham G. L., Westenkirchner D. F. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis. 1988 Mar;157(3):565–568. doi: 10.1093/infdis/157.3.565. [DOI] [PubMed] [Google Scholar]
  50. Shimamoto Y., Chen R. L., Bollon A., Chang A., Khan A. Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock. Immunol Lett. 1988 Apr;17(4):311–317. doi: 10.1016/0165-2478(88)90003-x. [DOI] [PubMed] [Google Scholar]
  51. Sigurdsson G. H., Christenson J. T., al-Mousawi M., Owunwanne A. Use of indium-111 oxine to study pulmonary and hepatic leukocyte sequestration in endotoxin shock and effects of the beta-2 receptor agonist terbutaline. Am J Physiol Imaging. 1989;4(4):136–142. [PubMed] [Google Scholar]
  52. Silva A. T., Appelmelk B. J., Buurman W. A., Bayston K. F., Cohen J. Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6. J Infect Dis. 1990 Aug;162(2):454–459. doi: 10.1093/infdis/162.2.454. [DOI] [PubMed] [Google Scholar]
  53. Stumacher R. J., Kovnat M. J., McCabe W. R. Limitations of the usefulness of the Limulus assay for endotoxin. N Engl J Med. 1973 Jun 14;288(24):1261–1264. doi: 10.1056/NEJM197306142882402. [DOI] [PubMed] [Google Scholar]
  54. Suffredini A. F., Fromm R. E., Parker M. M., Brenner M., Kovacs J. A., Wesley R. A., Parrillo J. E. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989 Aug 3;321(5):280–287. doi: 10.1056/NEJM198908033210503. [DOI] [PubMed] [Google Scholar]
  55. Suffredini A. F., Harpel P. C., Parrillo J. E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989 May 4;320(18):1165–1172. doi: 10.1056/NEJM198905043201802. [DOI] [PubMed] [Google Scholar]
  56. Sánchez-Cantú L., Rode H. N., Yun T. J., Christou N. V. Tumor necrosis factor alone does not explain the lethal effect of lipopolysaccharide. Arch Surg. 1991 Feb;126(2):231–235. doi: 10.1001/archsurg.1991.01410260121017. [DOI] [PubMed] [Google Scholar]
  57. Tahri-Jouti M. A., Mondange M., Le Dur A., Auzanneau F. I., Charon D., Girard R., Chaby R. Specific binding of lipopolysaccharides to mouse macrophages--II. Involvement of distinct lipid a substructures. Mol Immunol. 1990 Aug;27(8):763–770. doi: 10.1016/0161-5890(90)90085-e. [DOI] [PubMed] [Google Scholar]
  58. Taveira da Silva A. M., Kaulbach H. C., Chuidian F. S., Lambert D. R., Suffredini A. F., Danner R. L. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med. 1993 May 20;328(20):1457–1460. doi: 10.1056/NEJM199305203282005. [DOI] [PubMed] [Google Scholar]
  59. Toft P., Lillevang S. T., Tønnesen E., Svendsen P., Höhndorf K. Redistribution of lymphocytes following E. coli sepsis. Scand J Immunol. 1993 Dec;38(6):541–545. doi: 10.1111/j.1365-3083.1993.tb03238.x. [DOI] [PubMed] [Google Scholar]
  60. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  61. Ulevitch R. J. Recognition of bacterial endotoxin in biologic systems. Lab Invest. 1991 Aug;65(2):121–122. [PubMed] [Google Scholar]
  62. Wakefield C. H., Carey P. D., Foulds S., Monson J. R., Guillou P. J. Polymorphonuclear leukocyte activation. An early marker of the postsurgical sepsis response. Arch Surg. 1993 Apr;128(4):390–395. doi: 10.1001/archsurg.1993.01420160028003. [DOI] [PubMed] [Google Scholar]
  63. Warren H. S., Amato S. F., Fitting C., Black K. M., Loiselle P. M., Pasternack M. S., Cavaillon J. M. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med. 1993 Jan 1;177(1):89–97. doi: 10.1084/jem.177.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Warren H. S., Glennon M. L., Wainwright N., Amato S. F., Black K. M., Kirsch S. J., Riveau G. R., Whyte R. I., Zapol W. M., Novitsky T. J. Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect Immun. 1992 Jun;60(6):2506–2513. doi: 10.1128/iai.60.6.2506-2513.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. van Deventer S. J., Buller H. R., ten Cate J. W., Sturk A., Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet. 1988 Mar 19;1(8586):605–609. doi: 10.1016/s0140-6736(88)91412-2. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES